NCT05153525

Continuous Infusion Versus Intermittent Boluses of Cisatracurium in the Early Management of Pediatric ARDS

Continuous Infusion Versus Intermittent Boluses of Cisatracurium in the Early Management of Pediatric Acute Respiratory Distress Syndrome

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Tanta University · Academic / Other
• Sex: All
• Age: 1 Month – 18 Years
• Healthy volunteers: Not accepted

Summary

The aim of this work is to compare continuous infusion vs on need intermittent boluses of Cisatracurium in the early management of pediatric acute respiratory distress syndrome

Detailed description

In the pediatric population, Acute respiratory distress syndrome (ARDS) has a high mortality rate of approximately 24%. In addition, there is a lack of high-quality data to guide the use of non-depolarizing neuromuscular blocking agents (NMBAs) in mechanically ventilated children. Hence, there is a need to evaluate its use in pediatrics.

Conditions

• Respiratory Distress Syndrome, Pediatric
• Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)

Interventions

Type	Name	Description
DRUG	Intermittent boluses of Cisatracurium	Thirty children with ARDS will be treated with intermittent boluses of Cisatracurium (0.1-0.15 mg/kg/dose).
DRUG	Intravenous infusion of Cisatracurium for 24 hours	Thirty children with ARDS will be treated with intravenous infusion of Cisatracurium titrated from 1 mic/kg/min till reaching the desired effect for 24 hours.

Timeline

• Start date: 2022-01-06
• Primary completion: 2022-07-30
• Completion: 2022-08-05
• First posted: 2021-12-10
• Last updated: 2022-06-22

Locations

2 sites across 1 country: Egypt

Regulatory

• FDA-regulated drug study